≡

Myosin Heavy Chain 9, Non Muscle (MYH9)

[Edit]

DFNA17; EPSTS; FTNS; MHA; NMHC-II-A; NMMHCA; Nonmuscle Myosin Heavy Chain II-A; Cellular myosin heavy chain, type A; Myosin heavy chain, non-muscle IIa

Myosin Heavy Chain 9, Non Muscle (MYH9)
CCC D422
HGNC 7579
MGI 107717
PubMed 10973259
RGD 3140
UniProt P35579
Wiki MYH9
MYH9 polymorphisms are thought to contribute to glomerulosclerosis and non-diabetic end stage renal disease in African Americans.
This gene encodes a myosin IIA heavy chain that contains an IQ domain and a myosin head-like domain. The protein is involved in several important functions, including cytokinesis, cell motility and maintenance of cell shape. Defects in MYH9 are the cause of non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness. The genomic coordinates used for the transcript record were based on alignments.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPD422Hu01 Recombinant Myosin Heavy Chain 9, Non Muscle (MYH9) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAD422Hu01 Polyclonal Antibody to Myosin Heavy Chain 9, Non Muscle (MYH9) WB; IHC; ICC; IP.
MAD422Hu21 Monoclonal Antibody to Myosin Heavy Chain 9, Non Muscle (MYH9) WB; IHC; ICC; IP.
Assay Kits SED422Hu ELISA Kit for Myosin Heavy Chain 9, Non Muscle (MYH9) Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Myosin Heavy Chain 9, Non Muscle (MYH9) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Myosin Heavy Chain 9, Non Muscle (MYH9) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Myosin Heavy Chain 9, Non Muscle (MYH9) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Myosin Heavy Chain 9, Non Muscle (MYH9) CLIA Kit Customized Service Offer
n/a ELISA Kit for Myosin Heavy Chain 9, Non Muscle (MYH9) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Myosin Heavy Chain 9, Non Muscle (MYH9) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Myosin Heavy Chain 9, Non Muscle (MYH9) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Myosin Heavy Chain 9, Non Muscle (MYH9) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Myosin Heavy Chain 9, Non Muscle (MYH9) CLIA Kit Customized Service Offer
n/a ELISA Kit for Myosin Heavy Chain 9, Non Muscle (MYH9) ELISA Kit Customized Service Offer
  1. "A genome annotation-driven approach to cloning the human ORFeome."Genome Biol. 5:R84.1-R84.11(2004) [PubMed] [Europe PMC] [Abstract]
  2. "Vector-capping: a simple method for preparing a high-quality full-length cDNA library."DNA Res. 12:53-62(2005) [PubMed] [Europe PMC] [Abstract]
  3. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  4. "The DNA sequence of human chromosome 22." Nature 402:489-495(1999) [PubMed] [Europe PMC] [Abstract]
  5. "Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation."Blood 78:1826-1833(1991) [PubMed] [Europe PMC] [Abstract]
  6. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  7. "Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes."Circ. Res. 69:530-539(1991) [PubMed] [Europe PMC] [Abstract]
  8. , Submitted (AUG-2005) to UniProtKB
  9. "Human nonmuscle myosin heavy chain mRNA: generation of diversity through alternative polyadenylylation."Proc. Natl. Acad. Sci. U.S.A. 87:1164-1168(1990) [PubMed] [Europe PMC] [Abstract]
  10. "F-actin and myosin II binding domains in supervillin."J. Biol. Chem. 278:46094-46106(2003) [PubMed] [Europe PMC] [Abstract]
  11. "Proteomic identification of proteins conjugated to ISG15 in mouse and human cells."Biochem. Biophys. Res. Commun. 336:496-506(2005) [PubMed] [Europe PMC] [Abstract]
  12. "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks."Cell 127:635-648(2006) [PubMed] [Europe PMC] [Abstract]
  13. "A probability-based approach for high-throughput protein phosphorylation analysis and site localization."Nat. Biotechnol. 24:1285-1292(2006) [PubMed] [Europe PMC] [Abstract]
  14. "Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line."Electrophoresis 28:2027-2034(2007) [PubMed] [Europe PMC] [Abstract]
  15. "Supervillin slows cell spreading by facilitating myosin II activation at the cell periphery."J. Cell Sci. 120:3792-3803(2007) [PubMed] [Europe PMC] [Abstract]
  16. "Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment."J. Proteome Res. 7:5167-5176(2008) [PubMed] [Europe PMC] [Abstract]
  17. "Phosphoproteome of resting human platelets."J. Proteome Res. 7:526-534(2008) [PubMed] [Europe PMC] [Abstract]
  18. "MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis." Nat. Genet. 40:1175-1184(2008) [PubMed] [Europe PMC] [Abstract]
  19. "MYH9 is associated with nondiabetic end-stage renal disease in African Americans." Nat. Genet. 40:1185-1192(2008) [PubMed] [Europe PMC] [Abstract]
  20. "A quantitative atlas of mitotic phosphorylation."Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract]
  21. "Large-scale phosphoproteome analysis of human liver tissue by enrichment and fractionation of phosphopeptides with strong anion exchange chromatography."Proteomics 8:1346-1361(2008) [PubMed] [Europe PMC] [Abstract]
  22. "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach."Anal. Chem. 81:4493-4501(2009) [PubMed] [Europe PMC] [Abstract]
  23. "Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans."Kidney Int. 75:736-745(2009) [PubMed] [Europe PMC] [Abstract]
  24. "Large-scale proteomics analysis of the human kinome."Mol. Cell. Proteomics 8:1751-1764(2009) [PubMed] [Europe PMC] [Abstract]
  25. "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
  26. "Lysine acetylation targets protein complexes and co-regulates major cellular functions."Science 325:834-840(2009) [PubMed] [Europe PMC] [Abstract]
  27. "Myosin II motor proteins with different functions determine the fate of lamellipodia extension during cell spreading."PLoS ONE 5:E8560-E8560(2010) [PubMed] [Europe PMC] [Abstract]
  28. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  29. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  30. "System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation."Sci. Signal. 4:RS3-RS3(2011) [PubMed] [Europe PMC] [Abstract]
  31. "Application of the wheat-germ cell-free translation system to produce high temperature requirement A3 (HtrA3) proteases."BioTechniques 52:23-28(2012) [PubMed] [Europe PMC] [Abstract]
  32. "N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB."Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012) [PubMed] [Europe PMC] [Abstract]
  33. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  34. "Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9."Am. J. Hum. Genet. 67:1121-1128(2000) [PubMed] [Europe PMC] [Abstract]
  35. "Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes." Nat. Genet. 26:103-105(2000) [PubMed] [Europe PMC] [Abstract]
  36. "Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly."Nat. Genet. 26:106-108(2000) [PubMed] [Europe PMC] [Abstract]
  37. "Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes."Am. J. Hum. Genet. 69:1033-1045(2001) [PubMed] [Europe PMC] [Abstract]
  38. "Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions."J. Hum. Genet. 46:722-729(2001) [PubMed] [Europe PMC] [Abstract]
  39. "Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene."Hum. Genet. 110:182-186(2002) [PubMed] [Europe PMC] [Abstract]
  40. "Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes."J. Am. Soc. Nephrol. 13:65-74(2002) [PubMed] [Europe PMC] [Abstract]
  41. "Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome."Blood 102:529-534(2003) [PubMed] [Europe PMC] [Abstract]
  42. "Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations."Lab. Invest. 83:115-122(2003) [PubMed] [Europe PMC] [Abstract]
  43. "MYH9-related disease: may-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness." Medicine (Baltimore) 82:203-215(2003) [PubMed] [Europe PMC] [Abstract]
  44. "Macrothrombocytopenia and progressive deafness is due to a mutation in MYH9."Otol. Neurotol. 24:205-209(2003) [PubMed] [Europe PMC] [Abstract]
  45. "Bladder exstrophy and Epstein type congenital macrothrombocytopenia: evidence for a common cause?"Am. J. Med. Genet. A 140:2251-2253(2006) [PubMed] [Europe PMC] [Abstract]
  46. "The consensus coding sequences of human breast and colorectal cancers." Science 314:268-274(2006) [PubMed] [Europe PMC] [Abstract]
  47. "Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease." Hum. Mutat. 29:409-417(2008) [PubMed] [Europe PMC] [Abstract]